Jefferies Maintains Buy on ACIU (AC Immune S.A.) March 2026

Jefferies on March 13, 2026 maintained a Buy on AC Immune S.A. (ACIU), the main ACIU analyst rating update this week. The firm said “2025 financials largely immaterial,” signaling focus on longer term catalysts. StreetInsider reported the note and the stock moved roughly -0.66% (-$-0.02) on the news. This ACIU analyst rating keeps Jefferies aligned with a positive view while not supplying a price target, leaving valuation questions for investors.

ACIU analyst rating: Jefferies maintains Buy on March 13, 2026

Jefferies reiterated a Buy on ACIU on March 13, 2026 and described 2025 results as largely immaterial. The firm did not publish a new price target in the note. StreetInsider published the report and we link the note for reference source. The market reacted modestly with a -0.66% (-$-0.02) move on the day.

ACIU analyst rating context and recent coverage

This ACIU analyst rating is the sole formal change recorded on March 13, 2026. Only Jefferies is listed among recent analysts for this update. Analyst coverage for small biotech names can be intermittent, so each note carries relative weight for investors tracking AC Immune S.A.

What the maintained Buy means for investors

A maintained Buy means Jefferies keeps a favorable outlook, but it does not guarantee upside. Investors should view this ACIU analyst rating as confirmation of confidence in long term catalysts rather than short term earnings. Risk remains high for biotech stocks and investors should align position sizes with risk tolerance.

ACIU price target and valuation notes

Jefferies did not include a new price target in the March 13 note. With no price target, valuation relies on public comparables, clinical milestones, and cash runway. ACIU has a market cap of $303,309,000, which investors should weigh against pipeline progress and sector peers.

ACIU analyst rating and stock performance link

The March 13 ACIU analyst rating correlated with a small intraday price dip of -0.66%. Maintained ratings often reduce volatility compared with upgrades or downgrades. Traders may trade around catalysts, while longer term investors focus on clinical news and balance sheet updates.

Meyka AI view and risk grading for ACIU analyst rating

Meyka AI rates ACIU with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade supports a constructive but cautious stance. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Jefferies’ March 13, 2026 note maintained a Buy on AC Immune S.A., and that is the sole ACIU analyst rating update this period. The firm flagged 2025 financials as largely immaterial and supplied no price target, keeping valuation ambiguous. Investors should treat this maintained Buy as a reaffirmation of long term potential, not a short term catalyst. With a market cap of $303,309,000, ACIU remains a small cap biotech with higher volatility. Meyka AI rates ACIU with a grade of B, reflecting relative strength versus peers, growth expectations, and analyst alignment. Use this ACIU analyst rating alongside clinical milestones, cash runway checks, and your risk limits when deciding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.